Raymond James & Associates’s Myovant Sciences Ltd. MYOV Stock Holding History

Raymond James & Associates’s Portfolio MYOV Stock Details MYOV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-21,134	Closed	-$570K	–	4139
2022 Q4	$570K	Buy	+21,134	New	+$556K	﹤0.01%	2807
2021 Q3	–	Sell	-75,086	Closed	-$1.71M	–	4303
2021 Q2	$1.71M	Sell	75,086 -145	-0.2%	-$3.05K	﹤0.01%	2210
2021 Q1	$1.55M	Sell	75,231 -12,224	-14%	-$278K	﹤0.01%	2195
2020 Q4	$2.42M	Sell	87,455 -2,042	-2%	-$39.7K	﹤0.01%	1782
2020 Q3	$1.26M	Sell	89,497 -4,296	-5%	-$79.9K	﹤0.01%	2034
2020 Q2	$1.93M	Buy	93,793 +248	+0.3%	+$3.37K	﹤0.01%	1751
2020 Q1	$706K	Sell	93,545 -10,407	-10%	-$117K	﹤0.01%	2199
2019 Q4	$1.61M	Buy	+103,952	New	+$1.05M	﹤0.01%	1956

Other funds holding MYOV

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Raymond James & Associates's MYOV Position: Q1 2023 in Review

Raymond James & Associates sold out of Myovant Sciences Ltd. (MYOV) in Q1 2023, closing a stake of 21,134 shares — an estimated $570K sold.

Raymond James & Associates first reported a position in MYOV in Q4 2019 and held it in 8 quarters. The position peaked at $2.42M in Q4 2020. 2 funds tracked by Wall St. Rank hold MYOV as of Q1 2023.

Raymond James & Associates reported no remaining Myovant Sciences Ltd. position as of Q1 2023 after selling out during the quarter.
Raymond James & Associates sold 21,134 Myovant Sciences Ltd. shares in Q1 2023, an estimated $570K.
Raymond James & Associates first reported a position in Myovant Sciences Ltd. in Q4 2019 and held it in 8 quarters.
Raymond James & Associates's Myovant Sciences Ltd. position peaked at $2.42M in Q4 2020.
2 funds tracked by Wall St. Rank held Myovant Sciences Ltd. as of Q1 2023.

Based on Raymond James & Associates's 13F filing for Q1 2023, filed 14 Apr 2023.